SOPH
NASDAQSOPHiA GENETICS SA
News · 26 weeks163-18%
2026-03-012026-08-23
Mix5890d
- Insider39(67%)
- SEC Filings9(16%)
- Offering6(10%)
- Other2(3%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- SECSEC Form 144 filed by SOPHiA GENETICS SA144 - SOPHiA GENETICS SA (0001840706) (Subject)
- INSIDERChief People Officer Valente Manuela exercised 10,000 units of Ordinary Shares at a strike of $3.20 and sold $79,439 worth of Ordinary Shares (10,000 units at $7.94) as part of a pre-agreed trading plan (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $163,482 worth of Ordinary Shares (20,000 units at $8.17) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $30,076 worth of Ordinary Shares (4,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 586,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Medical Officer Menu Philippe sold $37,580 worth of Ordinary Shares (5,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 218,387 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERExecutive Chairman Camblong Jurgi sold $209,209 worth of Ordinary Shares (28,500 units at $7.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.82% to 3,444,322 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Technology Officer Verma Abhimanyu sold $38,000 worth of Ordinary Shares (5,000 units at $7.60) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 182,171 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu exercised 10,000 units of Ordinary Shares at a strike of $3.28 and sold $144,924 worth of Ordinary Shares (20,000 units at $7.25) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 590,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERExecutive Chairman Camblong Jurgi sold $138,412 worth of Ordinary Shares (20,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 3,472,822 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $69,168 worth of Ordinary Shares (10,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 600,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Technology Officer Verma Abhimanyu sold $34,772 worth of Ordinary Shares (5,000 units at $6.95) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 187,171 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Reports Second Quarter 2026 ResultsBOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsRevenue was $23.3 million, up 27% year-over-yearGross margin was 64.6% on a reported basis and 72.1% on an adjusted basis, compared to 67.0% reported and 74.4% adjusted in the prior year periodNet loss was $22.4 million, flat year-over-year; Adjusted EBITDA loss was $8.8 million, improving 27% year-over-yearThe company is raising 2026 revenue guidance to a range of $94 millio
- PRSOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology TherapiesBOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (NYSE:AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies. As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized comp
- INSIDERChief Medical Officer Menu Philippe sold $28,306 worth of Ordinary Shares (5,000 units at $5.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 223,387 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERExecutive Chairman Camblong Jurgi sold $286,099 worth of Ordinary Shares (44,381 units at $6.45) as part of a pre-agreed trading plan and exercised 4,581 units of Ordinary Shares at a strike of $3.16, decreasing direct ownership by 1% to 3,492,822 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRSOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.About SOPHiA GENETICSSO
- ANALYSTH.C. Wainwright initiated coverage on SOPHiA GENETICS SA with a new price targetH.C. Wainwright initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $12.00
- INSIDERChief Scientific Officer Xu Zhenyu sold $22,819 worth of Ordinary Shares (4,000 units at $5.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.65% to 610,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Medical Officer Menu Philippe sold $28,505 worth of Ordinary Shares (5,000 units at $5.70) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 228,387 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERExecutive Chairman Camblong Jurgi sold $47,791 worth of Ordinary Shares (8,500 units at $5.62) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 3,532,622 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERExecutive Chairman Camblong Jurgi sold $93,327 worth of Ordinary Shares (17,685 units at $5.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.50% to 3,541,122 units (SEC Form 4) to satisfy tax liability4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Financial Officer Cardoza George sold $8,419 worth of Ordinary Shares (1,592 units at $5.29) as part of a pre-agreed trading plan, decreasing direct ownership by 0.51% to 309,092 units (SEC Form 4) (tax withholding)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief People Officer Valente Manuela sold $21,430 worth of Ordinary Shares (4,241 units at $5.05) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 210,450 units (SEC Form 4) (tax liability)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Technology Officer Verma Abhimanyu sold $26,957 worth of Ordinary Shares (5,285 units at $5.10) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 192,171 units (SEC Form 4) (tax liability)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
SOPH FAQ
7 questionsWhat does SOPHiA GENETICS SA do?
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.Where does SOPH stock trade?
SOPHiA GENETICS SA (SOPH) is listed on NASDAQ.What sector and industry is SOPH in?
SOPHiA GENETICS SA operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SOPHiA GENETICS SA go public?
SOPHiA GENETICS SA (SOPH) completed its IPO in 2021.What are analysts saying about SOPH?
SOPHiA GENETICS SA has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2026-07-20.What companies are similar to SOPH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SOPH side-by-side with any of them on Quantisnow.How can I track SOPH on Quantisnow?
Quantisnow aggregates SOPHiA GENETICS SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SOPH to receive live email and push alerts on every new disclosure.